Guttate psoriasis
Methodology & AI Transparency ⓘ
Guttate psoriasis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinical triage of Guttate psoriasis (L40.4) in Skin & Dermatology relies on topical retinoids/calcineurin/steroid sparing in Guttate psoriasis (L40.4: regimens), guiding step-wise therapeutic adjustments toward 25-Hydroxy Vitamin D in Guttate psoriasis (L40.4: & hs-CRP) (25(OH)D 40–65 ng/mL (L40.4)).
- 2 Real-world patient consensus: Diagnostic registry L40.4: Guttate psoriasis is managed within Skin & Dermatology.
- 3 Typical cash cost range: Workup highlights for Guttate psoriasis (L40.4): topical retinoids/calcineurin/steroid sparing in Guttate psoriasis (L40.4: regimens).
- 4 Top reported side effects / signs: Longitudinal Guttate psoriasis monitoring tracks Fasting Lipids & in Guttate psoriasis (L40.4: ALT (if systemic) toward Within baseline reference limits (L40.4).
Ask our AI Specialists anything about Guttate psoriasis
What Is Guttate psoriasis?
Clinical triage of Guttate psoriasis (L40.4) in Skin & Dermatology relies on topical retinoids/calcineurin/steroid sparing in Guttate psoriasis (L40.4: regimens), guiding step-wise therapeutic adjustments toward 25-Hydroxy Vitamin D in Guttate psoriasis (L40.4: & hs-CRP) (25(OH)D 40–65 ng/mL (L40.4)).
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Guttate psoriasis (L40.4) center on cutaneous immune skewing in Guttate psoriasis (L40.4: (Th2/IL-4/IL-13 in atopic). targeted skin & dermatology interventions aim to normalize Fasting Lipids & in Guttate psoriasis (L40.4: ALT (if systemic).
Common Symptoms & Clinical Signs
- • Presentation of Guttate psoriasis (L40.4): compromised epidermal barrier in Guttate psoriasis (L40.4: with dryness, fissuring,)
- • Secondary Guttate psoriasis clinical sign: post-inflammatory hyperpigmentation, facial in Guttate psoriasis (L40.4: flushing, or pitted)
- • Symptom flares in Guttate psoriasis correlating with Fasting Lipids & in Guttate psoriasis (L40.4: ALT (if systemic) deviation outside Within baseline reference limits (L40.4)
- • Functional skin & dermatology impact requiring topical retinoids/calcineurin/steroid sparing in Guttate psoriasis (L40.4: regimens) evaluation (L40.4)
Guttate psoriasis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L40.4 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NLM Clinical Tables |
| Diagnostic / Lab Marker: Fasting Lipids & in Guttate psoriasis (L40.4: ALT (if systemic) | Within baseline reference limits (L40.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Guttate psoriasis (L40.4: & hs-CRP) | 25(OH)D 40–65 ng/mL (L40.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Affected Body Surface in Guttate psoriasis (L40.4: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L40.4) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Guttate psoriasis
Treatment selection for Guttate psoriasis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Guttate psoriasis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Acitretin versus etretinate in psoriasis. Clinical and how the body absorbs the Three weeks after cessation of drug administration, the plasma concentrations of acitretin were below the sensitivity level of the assay, whereas etretinate was still quantifiable. Journal of the American Academy of Dermatology • 1988-09-15 • Randomized Controlled Trial | N = 175 | 88/100 | PMID 2971692 ↗ |
| New Insights on Phase 3 trial demonstrating high efficacy, favourable safety and convenience of a: What a 490-Participant Study Found CAL/BDP PAD-cream is a novel applied to the skin treatment of psoriasis that has a high efficacy and a favourable safety profile combined with a superior patient-reported treatment convenience. Journal of the European Academy of Dermatology and Venereology : JEADV • 2023-11-15 • Phase III Randomized Trial | N = 490 | 87/100 | PMID 37432045 ↗ |
| New Insights on Biosimilar SB17 versus reference ustekinumab in moderate to severe plaque: What a 503-Participant Study Found SB17 demonstrated clinical biosimilarity to UST after switching from UST, and maintained long-term comparable real-world benefits and safety with UST up to Week 52. The Journal of dermatological treatment • 2024-12-15 • Phase III Randomized Trial | N = 503 | 87/100 | PMID 39658004 ↗ |
| Can This Approach Help? Inside the Latest Research on Polymer oxygenated alginate dressings for healing skin graft donor areas: A phase Our results demonstrate that POA dressing is safe and clinically effective for treating split-thickness skin graft donor site wounds. Burns : journal of the International Society for Burn Injuries • 2026-04-15 • Phase III Randomized Trial | N = 69 | 82/100 | PMID 41713054 ↗ |
| Can This Approach Help? Inside the Latest Research on Cumulative irritancy comparison of skin-applied retinoid and antimicrobial Adapalene gel 0.1% has tolerability superior to both tazarotene cream 0.05% and tretinoin microsphere 0.04% when used in applied to the skin combination therapy. Skinmed • 2006-01-15 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 16957432 ↗ |
Guttate psoriasis Patient Community & “People Like Me” Threads
Filter Guttate psoriasis community threads and patient logs by age, biological sex, dosage, and treatment duration.